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Phosphodiesterases (PDEs) shape local cAMP gradients
to underpin the speciﬁcity of receptor function. Key to
this process is the highly deﬁned nature of the intra-cel-
lular location of PDEs in the cell. PDE4A5 is a PDE
isoform that speciﬁcally degrades cAMP and is known
to associate with the p75 neurotrophin receptor
(p75NTR) where it modulates cAMP signalling cascades
that regulate extracellular matrix remodelling in the
lungs. Here we map and validate novel proteinprotein
interaction sites that are important for formation of the
PDE4A5p75NTR complex and show, for the ﬁrst time,
that phosphorylation of PDE4A5 by MAPKAPK2 en-
hances PDE4A5 interaction with p75NTR and that this,
in turn, serves to attenuate ﬁbrin degradation.
Keywords: cyclic-AMP; extracellular matrix;
p75-NTR; PDE4A; phosphodiesterase..
Abbreviations: AKAP, a-kinase anchoring protein;
ASK1, apoptosis signal-regulating kinase 1; cAMP,
cyclic adenosine monophostate; COX2, cyclooxygen-
ase 2; ERK, extracellular signal-regulated kinases;
HEK293, human embryonic kidney cells; IL, inter-
leukin; LPS, lipopolysaccharide; LR1, linker region 1;
MAP, mitogen-activated protein; MAPK, mitogen-
activated protein kinase; MEF, mouse embryonic
ﬁbroblast; MAPKAPK2—MK2, MAPK-activated
protein kinase 2; MAPKAPK3—MK3, MAPK-acti-
vated protein kinase 3; PAI-1, plasminogen activator
inhibitor 1; PDE, phosphodiesterase; PGE2, prosta-
glandin E2; PKA, protein kinase A; PMA, phorbol
12-myristate 13-acetate; p75NTR, p75 neurotrophin
receptor; Ser, serine; tPA, tissue plasminogen activa-
tor; TNF-a, tumour necrosis factor a; WT, wild type.
p38 Mitogen-activated protein kinase (MAPK) signal-
ling is integral to cellular inﬂammation and stress re-
sponses. Upon extracellular activation by cellular
stressors, such as oxidative stress or UV light, or
stimulation with cytokines or growth factors, p38
MAPK activates MK2 (MAPK-activated protein
kinase 2, MAPKAPK2) and the compensatory MK3
(MAPKAPK3) (1, 2). Numerous substrates of MK2
have been identiﬁed in both cytoplasmic and nuclear
compartments (3) and phosphorylation of these drives
the MK2 cellular response.
Cyclic adenosine monophosphate (cAMP), a ubiqui-
tous second messenger molecule, is employed widely by
Gs-coupled receptors to orchestrate a variety of receptor-
speciﬁc responses. PDEs (phosphodiesterases) are the
only known enzyme family that can breakdown cAMP,
making them crucial for the ﬁne control of receptor sig-
nalling cascades. Of the large PDE superfamily, PDE4 is
the most versatile as its 25 isoforms, encoded by four
genes, locate differentially within cells and tissues (4).
Using a combination of approaches, including siRNA-
mediated knockdown, peptide displacement and domin-
ant-negative isoforms, these enzymes have been shown to
have unique, non-redundant roles, which span from in-
ﬂammatory regulation to cardiac contractility (5).
Generally, the modular structures of PDE4 isoforms
contain an N-terminal targeting domain, which directs
them to speciﬁc subcellular locations, UCR1 and UCR2
(upstream-conserved regions 1 and 2), which act as regu-
latory regions, and a C-terminal catalytic domain (see
Fig. 1), which is highly conserved between isoforms (4).
The speciﬁc, subcellular targeting of individual
PDE4 enzymes underpins the functionality of each iso-
form and is vital to ensure receptor-speciﬁc responses
via the three dimensional shaping of cAMP gradients
that result from receptor activation (4, 6).
Compartmentalized degradation of cAMP in cells is
made possible by the ability of PDE4s to integrate into
macromolecular complexes, or signalosomes, via inter-
actions with different cellular scaffold proteins, such as
A-kinase anchoring proteins (AKAPs) and other signa-
losome components (4, 7). This paradigm also provides
a cellular desensitization mechanism, whereby compart-
mentalized increases in cAMP activate PKA (protein
kinase A) pools localized in the vicinity of the PDE4
in order to phosphorylate and activate long PDE4 iso-
forms (8). MK2 is also known to phosphorylate the
PDE4 isoform PDE4A5 (9), although this phosphoryl-
ation does not alter the PDE’s enzymatic activity on its
own. Instead, phosphorylation by MK2 attenuates the
activation triggered by PKA phosphorylation, disrupt-
ing cellular desensitization to cAMP. Additionally, the
MK2 phosphorylated PDE4A undergoes a conform-
ational change, which reduces its binding to interacting
proteins which associate with the UCR2 domain (9).
Recently, MK2 was shown to interact with PDE4A5
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with high ﬁdelity via two separate docking sites, with
such a process allowing for the efﬁcient phosphorylation
of PDE4A5 by this kinase (10).
The p75 neurotrophin receptor (p75NTR), although
most commonly known for its role in the nervous
system, also plays a role in respiratory inﬂammation
(11). This low afﬁnity receptor is unusual for a neuro-
trophin receptor, as it does not have any catalytic activ-
ity of its own. Instead, it functions by sequestering
other signalling molecules that mediate downstream sig-
nalling actions. One example of this type of signalling is
p75NTR’s regulation of ﬁbrin degradation. Fibrinolysis
is an integral part of the matrix remodelling process,
which contributes to tissue repair. Studies using mice
deﬁcient in p75NTR provided unequivocal evidence
that the receptor functions to block ﬁbrin degradation
(12). Vital to this important function is the receptor’s
interaction with the cAMP/PKA pathway. Speciﬁcally,
p75NTR’s direct interaction with PDE4A5 increases
local cAMP degradation, reducing the activation of
PKA (13, 14) resulting in the simultaneous down-
regulation of tissue plasminogen activator (tPA) and
up-regulation of plasminogen activator inhibitor-1
(PAI-1). These actions promote scar formation and
inhibit extracellular matrix remodelling. Previous at-
tempts to map the sites of PDE4p75NTR interaction
pinpointed domains in the C-terminal, LR1 (linker
region 1) and the catalytic regions, of the PDE4 as
being important, though little has been done to deﬁne
these sites and provide a functional assessment (13).
Here we revisited the mapping of the sites on PDE4A
that bind to the p75NTR intracellular domain and
report that sites in both the UCR2 and catalytic do-
mains of PDE4A5 are, functionally, the most import-
ant. Importantly, we show, for the ﬁrst time, that
phosphorylation of PDE4A by the p38MAPK down-
stream effector, MK2 enhances the interaction of
PDE4 with p75NTR restricting local cAMP in order
to reduce the degradation of ﬁbrin.
Materials and Methods
Peptide array
25-mer peptides were immobilized on cellulose membranes using an
Autospot Robot ASS222 (Intavis) as previously described (15).
Arrays were activated in 100% ethanol, washed in TBS-T and
blocked with 5% milk powder solution (Marvel), before incubation
in a solution of recombinant protein diluted in 1% milk powder
solution. Arrays were thoroughly washed in TBS-T and incubated
in a solution of the appropriate primary antibody diluted in 1% milk
powder solution. Again, the arrays were washed and incubated in a
solution of the appropriate secondary antibody-HRP conjugate
diluted in 1% milk powder solution. The arrays were subjected to
ﬁnal washes and visualized using chemiluminescence.
Cell culture
HEK-293 (human embryonic kidney 293) cells were maintained in
growth medium consisting of DMEM supplemented with 10% FBS
(foetal bovine serum), 1% penicillin/streptomycin, 1% L-glutamine
and 1% non-essential amino acids. NIH3T3 cells were maintained in
growth medium consisting of DMEM supplemented with 0.1% peni-
cillin/streptomycin, 2mM glutamine and 10% (v/v) NCS (newborn
calf serum). MEF cells were isolated from c57 mouse embryos and
maintained at the same temperature and atmosphere as NIH3T3
cells, in growth medium consisting of DMEM supplemented with
0.1% penicillin/streptomycin, 2mM glutamine and 10% (v/v) FBS
(foetal bovine serum). Cells were passaged at 90% conﬂuency. All
cells were maintained at 37C in an atmosphere of 5% CO2/95% air.
Where indicated, cells were treated with anisomycin (10 mg/ml), roli-
pram (10 mM), SB203580 (25 mM) and TNFa (10 mM).
PDE activity assay
Cyclic nucleotide phosphodiesterase activity assays were carried out
in a two-step radioassay, as previously described (16). Samples were
ﬁrst incubated with [8-3H] 3’, 5’-cyclic adenosine monophosphate
substrate. The labelled cAMP was then hydrolyzed to 5’-AMP by
PDEs in the sample. This was then incubated with snake venom,
which dephosphorylated the 5’-AMP to adenosine. Dowex ion ex-
change resin (1 : 1 : 1 ratio of Dowex : dH2O : EtOH) was then used
to separate the negatively charged cAMP from the uncharged ad-
enosine. Scintillation counting was used to measure the amount of
[8-3H] adenosine, which allowed the determination of the rate of
cAMP hydrolysis.
Fibrin breakdown assay
Fibrin matrices (0.1U/ml thrombin, 2.5U factor XIII, 2mg ﬁbrino-
gen, 2mg Na-citrate, 0.8mg NaCl, 3ml plasminogen per 1ml
DMEM) were added to cell culture plates and left to clot at room
temperature. The matrices were soaked with DMEM supplemented
with 10% NCS and 0.1% penicillin/streptomycin. Cells were seeded
upon the matrices at high density and maintained in medium
(DMEM supplemented with 10% NCS, 2mmol/l L-glutamine and
0.1% penicillin/streptomycin) for 812 days with medium and
replaced every 2 days. Where indicated, treatments were added in
fresh medium. Phase contrast microscopy (Zeiss) was used to ana-
lyze cell invasion into the 3D ﬁbrin matrix. Fibrin degradation was
quantiﬁed by weighing the remaining gel and determining the de-
crease in gel weight, which corresponds to ﬁbrin degradation.
DNAmanipulation
A QuikChange Site-Directed Mutagenesis Kit (Stratagene) was
used to carry out site-directed mutagenesis as per the manufacturer’s
instructions. The concentration was measured using a spectropho-
tometer (Nanodrop). Mini- and Maxi-prep Kits (Qiagen) were
used to produce puriﬁed plasmid DNA, which was eluted in sterile
water and stored at 20C.
Transfection
Where indicated, cells were transiently transfected using Polyfect
reagent (Qiagen) as described previously (9, 17).
Preparation ofwhole cell lysates
Whole cell lysates were prepared by washing cells in sterile PBS
before the addition of 3T3 lysis buffer (25mM HEPES, pH 7.5,
2.5mM EDTA, 50mM NaCl, 50mM NaF, 30mM sodium pyro-
phosphate, 10% (w/v) glycerol and 1% Triton X-100, supplemented
with Complete UltraTM protease inhibitors (Roche; 1 tablet per 10
mls buffer). Cells were scraped and mixed at 4C before clearing
using centrifugation. Cell lysates were stored at 80C. Protein con-
centration was determined using BSA as a standard with Bradford
reagent (Bio-Rad) and measured using a spectrophotometer.
Immunoprecipitation and immunoblotting
Whole cell lysates were pre-cleared by incubation with G-Sepharose
beads for at least 30min. Equalized, pre-cleared lysates were incu-
bated with the indicated antibody for a minimum of 3 h to allow the
formation of immunocomplexes. The immunocomplexes were cap-
tured by incubation with fresh G-Sepharose beads, washed and
eluted using Laemmli buffer and heat.
Immunoprecipitates and other protein samples were resolved
using SDS-PAGE and transferred onto nitrocellulose membranes.
Five percent milk powder dissolved in TBS-T was used to block
non-speciﬁc binding before incubation with the indicated primary
antibody diluted in 1% milk powder in TBS-T. The bound antibody
was detected using appropriate HRP-conjugated secondary antibo-
dies (Sigma-Aldrich), and visualized using enhanced chemilumin-
escence (Pierce).
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Results
PDE4A4 and p75NTR interact directly
Peptide array screening has been successfully utilized
by us previously to pinpoint sites of proteinprotein
interaction that tether PDE enzymes to a variety of
different protein complexes (see e.g. (15, 18, 19)).
Here we used this technique to identify the amino
acids that underpin the interaction between PDE4A4,
the human orthologue of rodent PDE4A5 and
p75NTR. Initial screening of 25-mer peptides that
spanned the entire sequence of PDE4A identiﬁed posi-
tive interaction sites for p75NTR within UCR2 and
the catalytic unit (Fig. 1). Subsequent alanine scanning
peptide arrays in which each amino acid was sequen-
tially mutated to an alanine residue highlighted E237,
Y251, K406 and K407 as being essential for the
Fig. 1 PDE4A4 mutants reduced interaction with p75 without altering enzymatic activity. (a) A schematic representation of PDE4A4. Full
length PDE4A4, in the form of immobilized peptide ‘spots’ of overlapping 25-mer peptides, sequentially shifted ﬁve positions, was overlaid with
puriﬁed His-p75-ICD. Detection of p75 by immunoblotting identiﬁed positively interacting peptides (dark spots) that were taken forward
for alanine scanning. The rows of spots show peptide arrays based on the 25-mer interacting peptides, Glu223Leu242, Tyr250Ser242 and
Leu404Iso450 in which the indicated peptide was mutated to alanine. These arrays were probed with His-p75-ICD and immunoblotting allowed
detection of interaction. Peptide spots circled indicate peptides in which alanine substitution eliminated interaction consistently, identifying
amino acids crucial for the interaction (n=4). (b) Wild-type or mutated GFP-PDE4A4 (E237A, Y251A, K406A, K407A, KK406/7AA) were
transfected into HEK-293 cells and lysates prepared. The lysates were subjected to PDE-activity assays in the indicated concentrations. The
mutations did not signiﬁcantly affect enzymatic activity (e). (d) Full length p75, in the form of immobilized peptide ‘spots’ of overlapping 25-mer
peptides, sequentially shifted ﬁve positions, was overlaid with puriﬁed GST-PDE4A5. Detection of GST by immunoblotting identiﬁed positively
interacting peptides (dark spots). (b and c) Lysates from NIH-3T3 ﬁbroblasts stably overexpressing p75NTR and transfected with GFP-PDE4A4
wt or the indicated mutants were subjected to immunoprecipitation and immunoblotted for GFP and p75. The Y251A mutation and the KK406/
7AA mutations signiﬁcantly decreased the amount of PDE4A4 bound p75 (*P50.05) when compared with control. Data shown are typical of
experiments performed at least 3 times.
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interaction (Fig. 1a). Further validation of these amino
acids was sought using site-speciﬁc mutations in
PDE4A4 constructs. Mutants and wild-type PDE4A4
were transfected into HEK-293 cells to produce lysates
for immunoprecipitation analysis. It was conﬁrmed by
PDE assay that these mutations did not affect the ac-
tivity of PDE4A4 (Fig. 1e). The level of PDE4A4 pre-
sent in p75 immunoprecipitates was signiﬁcantly
reduced when cells were transfected with Y251A and
KK406/7AA mutants compared to wild type (WT)
PDE4A4 (Fig. 1b and c). This data strongly suggests
that residues Y251 within UCR2 and KK406/7 within
the PDE4 catalytic subunit are essential for the inter-
action between PDE4A4 and p75NTR. Conversely,
interaction sites for PDE4A5 on P75 were discovered
within the juxta-membrane region of p75 using peptide
array (Fig. 1d). Our data agrees with previous experi-
ments that utilized truncated p75 forms, requiring
sequences between 275 and 343 (13).
p75NTR decreases fibrin degradation dependent on
PDE4 activity
As one of the binding sites for p75NTR was contained
within the UCR2 domain (Fig. 1) and previous work
has shown that phosphorylation of PDE4A4, by MK2,
alters the proteinprotein interactions of the PDE4 in
that area (10), we were keen to discover whether this
signalling axis could affect ﬁbrin degradation by mod-
ulating p75NTRPDE4A4 association. To do this we
established a ﬁbrin degradation assay in NIH/3T3 cells
stably expressing p75NTR (NIH/3T3-p75NTR cells).
NIH/3T3 cells are known to have little endogenous
p75NTR expression (20) and this was conﬁrmed
under the microscope in our study (Supplementary
Fig. 1). NIH/3T3-p75NTR cells exhibited a three-fold
reduction in ﬁbrin degradation compared to WT NIH/
3T3 cells, indicating that in the presence of p75NTR,
the process of ﬁbrinolysis is inhibited (Fig. 2a and b).
To verify that PDE4 activity associated with p75NTR is
Fig. 2 PDE4/p75 interaction, increased by MAPKAPKK2 phosphorylation of PDE4A5, reduces ﬁbrin degradation. (a) NIH3T3 cells and
NIH3T3 cells stably expressing p75 were seeded onto 3D ﬁbrin gels, subjected to treatment and subsequently analyzed for ﬁbrin degradation.
10 magniﬁcation of cells treated with PDE4 inhibitor rolipram (10 mM), anisomycin (10 mM) with or without pre-incubation with SB203580
(25 mM) or rolipram. (b) Quantitative analysis of three independent experiments performed as in (a) (*P50.05) when compared with control, (c)
p75 stable cells were treated with p38 MAP kinase activator, TNFa (10 mM), with or without pre-incubation with p38 MAPK kinase inhibitor,
SB203580 (25 mM). p75 was selectively immunoprecipitated (IP) and probed for PDE4A. (d) p75 stable cells transiently transfected with PDE4A5
were treated with p38 MAP kinase activator anisomycin (10 mg/ml) with or without SB203580 pre-incubation. IPs were performed as in (c). (e)
p75 stable cells transiently transfected with PDE4A5 S147A (phospho-null) were treated and immunoprecipitated as in (c).
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involved mechanistically in the ﬁbrinolysis process, we
treated the NIH3t3-p75NTR cells with PDE4 selective
inhibitor, rolipram. As expected, the three-fold reduc-
tion in ﬁbrin degradation promoted by p75NTR was
abolished following pharmacological attenuation of
PDE4 activity (Fig. 2a and b). To determine whether
phosphorylation of PDE4A4 by MK2 inﬂuences action
of the PDE4A4 pool associated with p75NTR, we trea-
ted NIH3t3-p75NTR cells with agents (TNFa or aniso-
mycin) that activate the p38 MAPK cascade and have
previously been shown to activate the downstream
kinase MK2 in such a way as to promote the phosphor-
ylation of PDE4A4 at Ser147, the MK2 consensus
phosphorylation site located within the UCR1 regula-
tory domain (7).
Immunopuriﬁcation of p75NTR from cell lysates
was undertaken and these probed for PDE4A4 in
order to determine whether PDE4A phosphorylation
had altered the ﬁdelity of interaction. To our surprise,
TNFa (tumour necrosis factor a) treatment, which
increased PDE4A4 phosphorylation by MK2 dramat-
ically increased association of stably over-expressed
p75NTR with endogenous PDE4A (Fig. 2c). This in-
crease in proteinprotein interaction could be ablated
by inhibition of p38MAPK signalling using the
p38MAPK inhibitor, SB203580 (Fig. 2c). In order to
verify that the MK2 phosphorylation of PDE4A4
underpins the increase in p75NTRPDE4A4 associ-
ation, we transiently transfected PDE4A5 wild type
(Fig. 2d) and PDE4A5 S147A (phospho-null)
(Fig. 2e) into NIH3t3-p75NTR cells, and repeated
the experiment with another MK2 activator anisomy-
cin. The increased amounts of p75NTRPDE4A com-
plex seen with endogenous PDE4A (Fig. 2c) were also
observed when PDE4A wild type was over-expressed
(Fig. 2d) but not with the corresponding phospho-null
mutant (Fig. 2e). Previous work had shown that MK2
phosphorylation could inhibit certain UCR2-depend-
ent proteinprotein interactions with PDE4A (e.g.
DISC1 and AIP) and not affect others (e.g. beta-
arrestin with PDE4D5) (9). Here we show that this
post-translational modiﬁcation can also enhance pro-
tein partner binding with p75NTR.
We next investigated whether increased PDE4/
p75NTR interaction had a functional role in ﬁbrin deg-
radation. Treatment of NIH/3T3-p75NTR with aniso-
mycin caused a profound loss of ﬁbrin degradation
from 19±2% in untreated cells to 1.4±1.1%
(n=4±SD) in treated cells (Fig. 2a and b). The treat-
ment had no effect on WT NIH/3T3 cells. This robust
functional effect can be ascribed to the increased seques-
tration of PDE4A5 by p75NTR, which would further
decrease the cAMP levels, ultimately causing a dramatic
reduction in the ﬁbrinolysis pathway. Incubation of
NIH/3T3-p75NTR cells with SB203580 before anisomy-
cin treatment resulted in a restoration of ﬁbrinolysis ac-
tivity comparable to untreated cells, which conﬁrmed
that the effects of anisomycin were due to the activation
of the p38 MAP kinase pathway, rather than any non-
speciﬁc, off target activities of such treatment (Fig. 2a
and b). Finally, when NIH/3T3-p75NTR cells were incu-
bated with rolipram prior to anisomycin treatment.
Under such circumstances, the level of ﬁbrin degradation
(35±3%) was markedly increased compared to treat-
ment with anisomycin alone (1.4±1.1%), but not quite
to the level of rolipram alone (51±9%) (n=4±SD),
suggesting that the two treatments had opposite effects
(Fig. 2a and b). The effects of p38 MAP kinase pathway
activation and the effects of PDE4 inhibition were com-
peting with each other to yield a result midway between
the two separate treatments.
Effects of PDE4A5/p75NTR interaction enhanced by
p38MAP kinase phosphorylation of PDE4A5 in pri-
mary cells
Having discovered a novel role for the p38 MAP
kinase pathway in the PDE4/p75NTR-mediated regu-
lation of ﬁbrinolysis in a stable cell line, we next
wanted to verify this concept in primary cells
(Fig. 3). Mouse embryonic ﬁbroblast cells (MEFs) iso-
lated from PDE4A knockout (PDE4A/) mice
showed more than a three-fold increase in ﬁbrin deg-
radation compared to MEFs from wild type (WT)
mice (Fig 3a and b). Inhibition of all PDE4 isoforms
with rolipram resulted in signiﬁcantly increased ﬁbrin
degradation in WT MEFs (57±3%) and this was
comparable with levels in PDE4A/ MEFs
(60±6%), whose ﬁbrinolysis activity was not altered
by rolipram treatment (Fig. 3a and b). Taken together,
these data support the notion of a non-redundant role
of PDE4A in the regulation of ﬁbrinolysis.
The role of PDE4A5 phosphorylation by MK2 was
also substantiated in MEF cells. Treatment with aniso-
mycin caused ﬁbrin degradation to be all but abol-
ished in WT MEFs (3±2%) while degradation in
PDE4A/ MEFs remained at basal levels (59±5%)
(Fig. 3a and b). When cells were treated with p38
MAPK inhibitor, SB203580, then the effects of the
p38MAPK activator, anisomycin on WT cells was
ablated, and the amount of ﬁbrin degradation
(20±5%) was no different from that observed in un-
treated cells (Fig. 3a and b). Consistent with results on
NIH/3T3 cells, the activation of the p38 MAPK path-
way, and subsequent phosphorylation of PDE4A5, re-
sulted in reduced ﬁbrin degradation due to increased
association of PDE4A5 with p75NTR.
To conﬁrm that the cAMP dynamics in the vicinity of
p75NTR are uniquely regulated by PDE4A, similar ex-
periments were undertaken in PDE4B/ MEFS
(Fig. 3g and h). These cells behaved no differently to
WT cells following treatment with rolipram and/or p38
MAPK activators and inhibitors. PDE4 inhibition re-
sulted in the same increase in ﬁbrin degradation in both
WT and PDE4B/MEFs while anisomycin caused the
opposite effect, decreasing ﬁbrin degradation. Finally,
the addition of anisomycin together with SB203580
ablated the stimulatory effect of anisomycin in both
WT and PDE4B/ knockout cells (Fig. 3g and h).
As PDE4A/ MEFs provide the perfect back-
ground for a ‘rescue’ experiment we wanted to conﬁrm
the role that MK2 phosphorylation plays by transi-
ently expressing PDE4A5 (Fig. 3i). To this end, wild
type PDE4A5 and a MK2-phosphorylation null
mutant (PDE4A5 S147A) were exogenously delivered
to PDE4A/ MEFS (Fig. 3i). Re-expression of WT
PDE4A5 in these cells resulted in a complete rescue of
Phosphorylated PDE4A5 attenuates fibrin degradation
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the effects seen in WT MEFs, while the MEFs over-
expressing PDE4A5 S147A reacted no differently than
the PDE4A/ cells (Fig. 3e and f). Reﬂecting the simi-
lar enzymatic activities of the PDE4A5 enzymes, the
inhibition of PDE4 with rolipram caused the same in-
crease in ﬁbrin degradation in cells ectopically express-
ing either WT or S147A PDE4A5. However, when the
p38 MAP kinase pathway was activated, cells
Fig. 3 Effects of PDE4A5/p75NTR interaction enhanced by p38 MAP kinase phosphorylation of PDE4A5. (a, b) WT MEF cells and PDE4A/
cells were seeded on 3D ﬁbrin gels, subjected to treatment and subsequently analyzed for ﬁbrin degradation. 10magniﬁcation of cells treated
with rolipram (10 mM) or anisomycin (10 mM) with or without pre-treatment with SB203580 (25 mM). A quantitative analysis of three inde-
pendent experiments (**P50.01) when compared with PDE4A/ mefs). (c, d) Experiments were repeated as in (a) this time including PDE4A/
 cells with PDE4A5 dominant negative (DN) reintroduced via transient transfection. A quantitative analysis of three independent experiments
(*P50.05) when compared with PDE4A5-D/N. (e, f) Experiments were repeated as in (a) using PDE4A/ cells with PDE4A5 or PDE4A5
S147A (phsopho-null mutant) reintroduced via transient transfection. A quantitative analysis of three independent experiments (**P50.01)
when compared with control (PDE4A5 transfected). (g, h) A quantitative analysis of three independent experiments using WT MEF cells and
PDE4B/MEF cells subjected to treatments as in (a). Data are means±SD. (i) Conﬁrmation of reintroduction of PDE4A5 forms via western
blotting.
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expressing WT PDE4A5 had decreased ﬁbrin degrad-
ation comparable to WT MEF cells. In striking con-
trast, the same treatment caused no signiﬁcant effect
on cells re-expressing PDE4A5 S147A. Such evidence
robustly supports the idea that PDE4A5 phosphoryl-
ation by MK2 results in a decrease in ﬁbrin degrad-
ation (Fig. 3e and f). Finally, to prove that increases in
PDE4 activity per se, rather than any other scaffolding
functions of PDE4, are responsible for changes in
ﬁbrinolysis, experiments were undertaken on
PDE4A/ MEFs—re-expressing either WT PDE4A5
or a dominant negative (D/N), catalytically inactive
PDE4A5 mutant (Fig. 3c and d). The D/N PDE4A5
clearly displaced the endogenous active PDE4A5 com-
ponent from p75NTR as ectopic expression of the
catalytically inactive, dominant negative, PDE4A5
mutant markedly increased the ﬁbrin degradation to
levels comparable to that observed by the PDE4A/
MEFs (65±5%) (Fig. 3c and d). Additionally, roli-
pram and anisomycin had no effects on the PDE4A/
MEFs these cells, which still displayed high levels of
ﬁbrin degradation.
Discussion
Cyclic-AMP signalling via p75NTR can inhibit scar
formation and suppress extracellular matrix remodel-
ling and these positive outcomes are opposed by
recruitment of PDE4A to the receptor (13, 14). We
report that that this process is also ﬁne-tuned by phos-
phorylation of PDE4A5 by MAPKAPK2, the down-
stream kinase of the p38 MAPK inﬂammatory
signalling cascade.
Much literature exists on the roles that p38MAPK
has in the orchestration of signalling events involved in
inﬂammatory responses in a range of cell types. Of
particular importance is the ability of the kinase to
coordinate downstream signalling in macrophages
challenged with LPS, monocytes exposed to IL-18
and neutrophils activated by phorbol 12-myristate
13-acetate (PMA) or TNFa (21, 22). Data from p38
null mice also suggest that p38 activity is important for
the production of TNFa, Interleukin (IL)-1b and
IL-10 via Toll-like receptor 4 signalling (23). Indeed,
p38MAPK has been linked to the production of a
variety of pro-inﬂammatory mediators such as IL-12,
IL-1b, TNF-a, prostaglandin E2 (PGE2) and IL-12 as
well as cyclooxygenase 2 (COX-2), IL-8, IL-6, IL-3,
IL-2 and IL-1 (reviewed in (24)). Correspondingly,
p38MAPK inhibitors are now being assessed as anti-
inﬂammatory agents (25). In the context of the lung,
p38MAPK inhibitors have been shown to protect
against LPS (lipopolysaccharide)induced acute lung
inﬂammation by retarding LPS triggered production
of TNFa (26). Interestingly, increase levels of activated
p38 have been observed in the lungs of chronic ob-
structive pulmonary disease (COPD) patients (27,
28), and p38MAPK inhibitors have been thought of
as a therapeutic target for the disease for over a
decade (29). Recent double-blind, randomized, pla-
cebo-controlled trials of p38MAPK inhibitors in
COPD patients have shown promising results. The
ﬁrst trial looked at whole-blood bio-markers and
found that p38MAPK inhibition signiﬁcantly reduced
the phosphorylation of HSP-27 (a p38 substrate) and
LPS-induced TNFa production (30). The second trial
assessed changes in lung function and reported an in-
crease in forced expiratory volume in COPD patients
assigned to p38MAPK inhibition therapy (31) and the
third observed that P38 inhibition could reduce plasma
ﬁbrinogen levels of patients (32). Fibrinogen has been
characterized as a negative biomarker for COPD i.e.
associated with poor clinical outcomes (33).
Indeed p38MAPK signalling (via activation of
ASK1 (apoptosis signal-regulating kinase 1)) has also
been implicated in the deposition of ﬁbrin following
the up-regulation of tissue factor in acute lung injury
caused by sepsis (34). Additionally, modulation of the
p38MAPK pathway by intracellular glutathione in-
hibits plasminogen activator inhibitor-1 (PAI-1) ex-
pression in a cellular model of pulmonary ﬁbrosis
(35). Taken as a whole, the above information robustly
indicates that p38MAPK activity exacerbates inﬂam-
matory signalling associated with COPD and has the
ability to regulate extracellular matrix remodelling in
the lungs. The data we present here describes a new
mechanism that may underpin both of these functions.
The mechanism relies on the activation of
MAPKAPK2 by p38MAPK and the subsequent phos-
phorylation of PDE4 by MAPKAPK2 (Fig. 4).
This action enhances the PDE’s interaction with
p75NTR causing a paucity of cAMP around the
receptor and a concomitant diminution of ﬁbrin break-
down (Fig. 4). This concept is supported by data sug-
gesting that both p38MAPK inhibitors and PDE4
inhibitors are capable of attenuating TNFa release in
COPD in alveolar macrophages isolated from COPD
lung transplant tissue (36).
The speciﬁcity of the interaction between only
PDE4A (but not PDE4B, C or D) enzymes and
p75NTR identiﬁes this proteinprotein interaction as
a new potential target for therapeutic intervention,
however, the use of pharmacological approaches to
inhibit the active site of PDE4s in this setting has
lacked success due to side-effects caused by lack of
speciﬁcity relating to the highly homologous catalytic
domain i.e. almost identical in all PDE4 isoforms.
Efforts to counteract this problem have resulted in
the development of PDE4B (37) and PDE4D (38, 39)
selective inhibitors, which have been directed toward
disease states such as Alzheimer’s disease. In this con-
text, both inhibitor types can play a role with PDE4B
inhibition attenuating neuro-inﬂammation by reducing
cytokine production in the brain following beta-amyl-
oid insult, whereas PDE4D compounds act to augment
phospho-CREB enhancing cognition (40). To date,
however, efforts to develop a pharmacological ap-
proach to speciﬁcally attenuate PDE4A activity have
not been fruitful (41).
As the functions of individual PDE4 isoforms are
dictated by their discrete cellular location (7), displa-
cing localized PDE4 ‘pools’ from their site of action is
a therapeutic strategy that has potential in this context
(42). Detailed information on the docking sites for
both protein partners is required for this approach
and here we provide evidence of novel binding sites
Phosphorylated PDE4A5 attenuates fibrin degradation
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on PDE4A for p75NTR in the UCR2 and catalytic
domains. The latter domain is of interest as recently
UCR2 has been recognized as a binding partner for
integrin a5 and this interaction serves to target
PDE4s to focal adhesions to promote pro-inﬂamma-
tory actions (43). Interestingly, integrin a5 association
suppresses the inhibitory phosphorylation of the PDE4
within the catalytic site by ERKMAP kinase, ensuring
that highly active PDE is available in focal adhesions
to regulate inﬂammatory signalling. Other PDE4 bind-
ing partners that use UCR2 as a docking domain
include AIP (aryl hydrocarbon receptor interacting
protein) (44) and DISC1 (45). Both of these are
released from PDE4A5 following phosphorylation of
the PDE on serine 147 by MK2 (9), whereas the pre-
sent study provides proof that the interaction of
PDE4A5 and P75 is enhanced following this post-
translational modiﬁcation. Such evidence suggests
that the modiﬁcation of serine 147 on PDE4A5 acts
as a relocation ‘switch’ to tailor the binding partner
proﬁle of the enzyme in order to shape cAMP gradi-
ents in discrete cellular locations (Fig. 4). In the lung,
enhancement of localized PDE4A5 activity in the
vicinity of P75 caused by MK2 phosphorylation
would lead to deleterious promotion of scar formation
and this could be of particular concern to COPD
patients where the human form of the enzyme
(PDE4A4) is selectively upregulated (46). Hence local
inhibition of p38MAPK or downstream kinase MK2
may represent an alternative strategy to the disruption
of the PDE4AP75 complex proposed above.
Supplementary Data
Supplementary Data are available at JB Online.
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